JP Morgan Maintains Underweight on Energizer Hldgs, Raises Price Target to $29
NCR Voyix Price Target Cut to $16.00/Share From $19.00 by RBC Capital
Ligand Pharmaceuticals Analyst Ratings
RBC Capital Reiterates Outperform on Ligand Pharmaceuticals, Maintains $130 Price Target
RBC Capital Maintains Outperform on NCR Voyix, Lowers Price Target to $16
JP Morgan Maintains Overweight on AnaptysBio, Raises Price Target to $75
Pactiv Evergreen Analyst Ratings
Vivid Seats Price Target Cut to $7.00/Share From $8.00 by RBC Capital
RBC Capital Maintains Outperform on Pactiv Evergreen, Lowers Price Target to $13
Canaccord Genuity Upgrades Rapid7 to Buy From Hold, Adjusts Price Target to $43 From $52
MBIA Analyst Ratings
Agilon Health Price Target Maintained With a $8.00/Share by RBC Capital
V2X Analyst Ratings
Buy Rating Affirmed for International Money Express Amid Digital Growth and Valuation Opportunity
RBC Capital Reiterates Outperform on V2X, Maintains $55 Price Target
Agilon Health Analyst Ratings
Xenia Hotels & Resorts Analyst Ratings
Beam Therapeutics Price Target Cut to $31.00/Share From $33.00 by Barclays
Applied Optoelectronics Price Target Cut to $9.00/Share From $12.00 by B. Riley Securities
Buy Rating Affirmed on Adtran Despite Industry Challenges and Revenue Dip, Highlighting Long-Term Growth Potential